Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dasiglucagon - Zealand Pharma/Novo Nordisk

Next Previous
X
Search
Drug Profile

Dasiglucagon - Zealand Pharma/Novo Nordisk

Alternative Names: HypoPal rescue pen; ZEGALOGUE; Zegalogue®; ZP 4207; ZP-GA-1

Latest Information Update: 11 Oct 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zealand Pharma
  • Developer Beta Bionics; Zealand Pharma
  • Class Antihyperglycaemics; Antihypoglycaemics; Peptides
  • Mechanism of Action Glucagon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Congenital hyperinsulinism
  • New Molecular Entity Yes
  • Available For Licensing Yes - Congenital hyperinsulinism

Highest Development Phases

  • Marketed Hypoglycaemia
  • Preregistration Congenital hyperinsulinism
  • Phase II/III Type 1 diabetes mellitus

Most Recent Events

  • 09 Oct 2024 Zealand Pharma receives complete response letter from the US FDA for Dasiglucagon for Hypoglycemia
  • 11 Sep 2024 Novo Nordisk plans a phase III trial for Hypoglycemia (in patients with Type 1 diabetes mellitus) (In children, In adolescents, In adults, In the elderly) in Japan (SC), in September 2024 (NCT06588504)
  • 31 May 2024 Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issues a positive opinion and recommends marketing authorization approval for dasiglucagon for Hypoglycaemia (In adolescents, In adults, In children)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top